1. Signaling Pathways
  2. Metabolic Enzyme/Protease
  3. Plasminogen/Plasmin

Plasminogen/Plasmin (纤溶酶原/纤溶酶)

Plasmin, the proteolytically active form of plasminogen, utilizes fibrin contained within clots as a substrate for proteolysis, producing soluble products and thus maintaining the patency within the vascular system. The precursor to plasmin, plasminogen, serves as zymogen produced by the liver circulates throughout the endovascular network, and participates in the fibrinolytic pathway, serving as both a catalytic enzyme to initiate the process of fibrinolysis, as well as a substrate, which once cleaved to become plasmin, continues on the process of fibrinolysis at an accelerated rate.

Plasminogen/Plasmin 相关产品 (6):

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-185319A
    Pexamsiran sodium Inhibitor
    Pexamsiran (sodium) 是一种 siRNA,能够抑制纤溶酶原合成,可用于遗传性出血性毛细血管扩张症的研究。
    Pexamsiran sodium
  • HY-P10005
    D-Val-Gly-Arg-pNA
    D-Val-Gly-Arg-pNA 是 TPA (组织纤溶酶原激活剂) 的显色底物。D-Val-Gly-Arg-pNA 可用于检测 TPA I 和 TPA II 的酰胺分解活性。
    D-Val-Gly-Arg-pNA
  • HY-182600
    KLK6-IN-1 Inhibitor
    KLK6-IN-1 是 KLK6KLK1 和纤溶酶 (plasmin) 的可逆性小分子抑制剂。KLK6-IN-1 对 KLK6、KLK1、纤溶酶的 IC50 值分别为 1.57 μM (KLK6)、5.1 μM (KLK1)、7.4 μM (plasmin),Ki 值分别为 0.8 μM (KLK6)、2.4 μM (KLK1)、1.3 μM (plasmin)。KLK6-IN-1 对 KLK6 及其蛋白水解网络具有高度选择性。KLK6-IN-1 可通过促进少突胶质前体细胞成熟来诱导少突胶质细胞分化。KLK6-IN-1 可用于多发性硬化症的研究。
    KLK6-IN-1
  • HY-185319
    Pexamsiran Inhibitor
    Pexamsiran 是一种 siRNA,能够抑制纤溶酶原合成,可用于遗传性出血性毛细血管扩张症的研究。
    Pexamsiran
  • HY-182565
    PSI-112 Inhibitor
    PSI-112 是一种 YO 类 μPlm 抑制剂,对野生型、F587A 突变型、K607A 突变型的 IC50 值分别为 0.38 μM、1.48 μM 和 0.37 μM。PSI-112 对 uPA 的亲和力较低。PSI-112 可用于癌症的研究。
    PSI-112
  • HY-P10005A
    D-Val-Gly-Arg-pNA acetate
    D-Val-Gly-Arg-pNA acetate 是 TPA (组织纤溶酶原激活剂) 的显色底物。D-Val-Gly-Arg-pNA acetate 可用于检测 TPA I 和 TPA II 的酰胺分解活性。
    D-Val-Gly-Arg-pNA acetate